RxDoctor Payments Data

Jose Audie Lim, MD

Internal Medicine · Wichita Falls, TXNPI 1548379696

Payments from drug & device makers

$1,490in general payments, 2019–2025

Across 64 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$376
  • Novo Nordisk$290
  • Bayer$282
  • Amarin Pharma, Inc.$111
  • Pfizer$98
  • GSK$88
  • plus $244 from 7 others

What the payments were for

  • Food & beverage$1,45297%
  • Education$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,490 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$93,275
Medicare patients
177
Services billed
1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate48$38,606
OzempicSemaglutide32$32,972
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,056
Humalog Kwikpen U-100Insulin Lispro33$18,349
EliquisApixaban16$17,183
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$10,150
LinzessLinaclotide16$8,326
SymbicortBudesonide/Formoterol Fumarate27$7,316
Levemir FlexpenInsulin Detemir26$6,540
MovantikNaloxegol Oxalate15$6,263
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,137
Tresiba Flextouch U-100Insulin Degludec14$4,973
Insulin Lispro Kwikpen U-100Insulin Lispro23$4,179
Tolterodine Tartrate ErTolterodine Tartrate21$3,077
Gabapentin279$2,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$30$38,60648 claims
Novo NordiskOzempic$290$32,97232 claims
GSKTrelegy Ellipta$88$28,05640 claims
PfizerEliquis$98$17,18316 claims
AbbVieLinzess$65$8,32616 claims
AstraZenecaSymbicort$376$7,31627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →